Handel Angion Biomedica Corp. - ANGN CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Spænd | 0.0341 | ||||||||
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.024068% | ||||||||
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.001846% | ||||||||
Gebyr natten over, tid | 21:00 (UTC) | ||||||||
Min. handlet mængde | 1 | ||||||||
Valuta | USD | ||||||||
Margen | 20% | ||||||||
Aktiebørs | United States of America | ||||||||
Kommission på handel | 0% |
*Information provided by Capital.com
Tidligere luk* | 0.4887 |
Åben* | 0.4791 |
1-Års Ændring* | -76.97% |
Dagens Spænd* | 0.4791 - 0.489 |
52-Ugers Spænd | 0.46-2.41 |
Gennemsnitlig Volumen (10 dage) | 28.11K |
Gennemsnitlig Volumen (3 måneder) | 1.42M |
Market Cap | 14.76M |
P/E-forhold | -100.00K |
Udestående aktier | 30.11M |
Omsætning | 2.30M |
EPS | -1.29 |
Dividend (Udbytte %) | N/A |
Beta | -100.00K |
Næste indtjeningsopgørelse | Mar 28, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Luk | Change | Change (%) | Åben | High | Low |
---|---|---|---|---|---|---|
Mar 22, 2023 | 0.4887 | 0.0096 | 2.00% | 0.4791 | 0.4890 | 0.4791 |
Mar 21, 2023 | 0.4789 | 0.0248 | 5.46% | 0.4541 | 0.4791 | 0.4493 |
Mar 20, 2023 | 0.4881 | 0.0001 | 0.02% | 0.4880 | 0.4986 | 0.4739 |
Mar 17, 2023 | 0.4887 | -0.0490 | -9.11% | 0.5377 | 0.5378 | 0.4823 |
Mar 16, 2023 | 0.5081 | 0.0198 | 4.05% | 0.4883 | 0.5695 | 0.4883 |
Mar 15, 2023 | 0.4930 | -0.0542 | -9.90% | 0.5472 | 0.5671 | 0.4888 |
Mar 14, 2023 | 0.5372 | -0.0196 | -3.52% | 0.5568 | 0.5963 | 0.5372 |
Mar 13, 2023 | 0.5377 | -0.0240 | -4.27% | 0.5617 | 0.5621 | 0.5208 |
Mar 10, 2023 | 0.5132 | -0.0641 | -11.10% | 0.5773 | 0.5778 | 0.5054 |
Mar 9, 2023 | 0.5568 | -0.0604 | -9.79% | 0.6172 | 0.6256 | 0.5375 |
Mar 8, 2023 | 0.5960 | 0.0078 | 1.33% | 0.5882 | 0.6158 | 0.5882 |
Mar 7, 2023 | 0.6060 | -0.0094 | -1.53% | 0.6154 | 0.6155 | 0.6056 |
Mar 6, 2023 | 0.6256 | -0.0208 | -3.22% | 0.6464 | 0.6466 | 0.6079 |
Mar 3, 2023 | 0.6156 | 0.0290 | 4.94% | 0.5866 | 0.6258 | 0.5865 |
Mar 2, 2023 | 0.5969 | 0.0009 | 0.15% | 0.5960 | 0.6130 | 0.5960 |
Mar 1, 2023 | 0.5883 | -0.0370 | -5.92% | 0.6253 | 0.6256 | 0.5855 |
Feb 28, 2023 | 0.6258 | 0.0006 | 0.10% | 0.6252 | 0.6452 | 0.6252 |
Feb 27, 2023 | 0.6453 | 0.0001 | 0.02% | 0.6452 | 0.6454 | 0.6451 |
Feb 24, 2023 | 0.6455 | 0.0006 | 0.09% | 0.6449 | 0.6736 | 0.6264 |
Feb 23, 2023 | 0.6449 | -0.0001 | -0.02% | 0.6450 | 0.6454 | 0.6367 |
Angion Biomedica Corp. Events
Tid (UTC) (UTC) | Land | Begivenhed |
---|---|---|
No events scheduled |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
Total omsætning | 28.312 | 2.88 | 1.487 | 4.029 |
Omsætning | 28.312 | 2.88 | 1.487 | 4.029 |
Kost af omsætning, Total | 0.433 | 1.19 | 0.64 | 0.378 |
Bruttofortjeneste | 27.879 | 1.69 | 0.847 | 3.651 |
Totale Driftsudgifter | 66.714 | 58.153 | 40.078 | 18.371 |
Salgs/Generelle/Admin. Udgifter, Total | 18.488 | 17.986 | 9.601 | 5.391 |
Forskning & Udvikling | 48.698 | 38.977 | 29.837 | 12.602 |
Driftsindtægter | -38.402 | -55.273 | -38.591 | -14.342 |
Renteindkomst (Udgift), Netto Ikke-Drift | -2.191 | -8.249 | 0.488 | 0.401 |
Andre, Netto | -13.98 | -16.527 | -2.555 | -6.084 |
Netto Indkomst Før Skat | -54.573 | -80.107 | -40.658 | -20.025 |
Netto Indkomst Efter Skat | -54.573 | -80.107 | -40.658 | -20.025 |
Netto Indkomst Før Ekstra Ting | -54.573 | -80.107 | -40.658 | -20.025 |
Netto Indkomst | -54.573 | -80.107 | -40.658 | -20.025 |
Total Adjustments to Net Income | 0 | -4.98 | ||
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -54.573 | -80.107 | -40.658 | -25.005 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -54.573 | -80.107 | -40.658 | -25.005 |
Fortyndet Netto Indkomst | -54.573 | -80.107 | -40.658 | -25.005 |
Fortyndet Vægtet Gennemsnit Aktier | 28.2448 | 14.7621 | 9.97635 | 9.97635 |
Fortyndet EPS Uden Ekstraordinære Ting | -1.93214 | -5.42652 | -4.07544 | -2.50643 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
Fortyndet Normaliseret EPS | -1.96418 | -5.4226 | -4.07544 | -2.50643 |
Gain (Loss) on Sale of Assets | 0 | -0.058 | ||
Usædvanlig Udgift (Indkomst) | -0.905 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total omsætning | 1.648 | 25.941 | 1.46 | 0.54 | 0.371 |
Omsætning | 1.648 | 25.941 | 1.46 | 0.54 | 0.371 |
Kost af omsætning, Total | 0.433 | 0 | 0 | 0 | |
Bruttofortjeneste | 25.508 | 1.46 | 0.54 | 0.371 | |
Totale Driftsudgifter | 16.133 | 11.307 | 17.218 | 17.879 | 20.31 |
Salgs/Generelle/Admin. Udgifter, Total | 4.466 | 4.206 | 3.93 | 4.34 | 6.012 |
Forskning & Udvikling | 11.667 | 6.668 | 13.288 | 14.444 | 14.298 |
Driftsindtægter | -14.485 | 14.634 | -15.758 | -17.339 | -19.939 |
Renteindkomst (Udgift), Netto Ikke-Drift | 0.206 | -0.016 | -0.074 | 0.067 | -2.168 |
Andre, Netto | 0.039 | 0.272 | 0.128 | 0.2 | -14.58 |
Netto Indkomst Før Skat | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
Netto Indkomst Efter Skat | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
Netto Indkomst Før Ekstra Ting | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
Netto Indkomst | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
Fortyndet Netto Indkomst | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
Fortyndet Vægtet Gennemsnit Aktier | 29.9592 | 29.9654 | 29.8296 | 29.6703 | 23.4438 |
Fortyndet EPS Uden Ekstraordinære Ting | -0.47531 | 0.49691 | -0.52646 | -0.57539 | -1.56489 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Fortyndet Normaliseret EPS | -0.47531 | 0.49691 | -0.52646 | -0.60589 | -1.56489 |
Usædvanlig Udgift (Indkomst) | 0 | 0 | -0.905 | ||
Gain (Loss) on Sale of Assets | 0 |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
Totale Nuværende Aktiver | 91.247 | 42.297 | 6.106 | 25.679 |
Likvider og Kortsigtede Investeringer | 88.756 | 34.607 | 5.571 | 25.512 |
Likvider & Lignende | 88.756 | 34.607 | 5.571 | 25.512 |
Totale Tilgodehavender, Netto | 0.806 | 5 | 0.44 | 0.107 |
Prepaid Expenses | 1.031 | 0.352 | 0.095 | 0.06 |
Total Assets | 96.513 | 47.347 | 11.886 | 26.628 |
Property/Plant/Equipment, Total - Net | 4.437 | 4.228 | 4.781 | 0.017 |
Property/Plant/Equipment, Total - Gross | 4.954 | 4.654 | 5.109 | 0.295 |
Accumulated Depreciation, Total | -0.517 | -0.426 | -0.328 | -0.278 |
Long Term Investments | 0.723 | 0.822 | 0.999 | 0.932 |
Total Current Liabilities | 11.296 | 107.449 | 26.575 | 7.355 |
Accounts Payable | 4.71 | 5.578 | 11.239 | 0.534 |
Accrued Expenses | 4.113 | 7.276 | 3.694 | 2.98 |
Notes Payable/Short Term Debt | 0 | 51.43 | 5.848 | 0 |
Other Current Liabilities, Total | 2.415 | 43.165 | 5.794 | 3.841 |
Total Liabilities | 15.006 | 137.796 | 30.472 | 7.717 |
Total Long Term Debt | 0.235 | 0.635 | 0 | 0 |
Other Liabilities, Total | 3.475 | 29.712 | 3.897 | 0.362 |
Total Equity | 81.507 | -90.449 | -18.586 | 18.911 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | |
Common Stock | 0.3 | 0.156 | 0.095 | 0.094 |
Additional Paid-In Capital | 296.445 | 72.136 | 63.584 | 60.138 |
Retained Earnings (Accumulated Deficit) | -215.135 | -160.562 | -80.455 | -39.797 |
Treasury Stock - Common | 0 | -1.846 | -1.81 | -1.524 |
Total Liabilities & Shareholders’ Equity | 96.513 | 47.347 | 11.886 | 26.628 |
Total Common Shares Outstanding | 29.9591 | 15.3167 | 9.97635 | 9.97635 |
Other Current Assets, Total | 0.654 | 2.338 | ||
Long Term Debt | 0 | 0.635 | ||
Other Equity, Total | -0.103 | -0.333 | ||
Other Long Term Assets, Total | 0.106 | |||
Current Port. of LT Debt/Capital Leases | 0.058 | |||
Capital Lease Obligations | 0.235 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 76.239 | 91.247 | 104.393 | 119.702 | 133.498 |
Likvider og Kortsigtede Investeringer | 73.002 | 88.756 | 102.736 | 117.313 | 130.456 |
Likvider & Lignende | 73.002 | 88.756 | 102.736 | 117.313 | 130.456 |
Totale Tilgodehavender, Netto | 0 | 0.806 | 0 | 0 | 0 |
Prepaid Expenses | 0.021 | 1.031 | 1.018 | 1.761 | 2.343 |
Other Current Assets, Total | 3.216 | 0.654 | 0.639 | 0.628 | 0.699 |
Total Assets | 81.258 | 96.513 | 109.94 | 125.359 | 139.2 |
Property/Plant/Equipment, Total - Net | 4.209 | 4.437 | 4.652 | 4.776 | 4.787 |
Property/Plant/Equipment, Total - Gross | 4.758 | 4.954 | 5.137 | 5.231 | 5.219 |
Accumulated Depreciation, Total | -0.549 | -0.517 | -0.485 | -0.455 | -0.432 |
Long Term Investments | 0.732 | 0.723 | 0.862 | 0.843 | 0.877 |
Other Long Term Assets, Total | 0.078 | 0.106 | 0.033 | 0.038 | 0.038 |
Total Current Liabilities | 10.381 | 11.296 | 17.946 | 20.524 | 16.963 |
Accounts Payable | 3.433 | 4.71 | 7.679 | 9.307 | 6.69 |
Accrued Expenses | 6.16 | 4.113 | 6.219 | 5.522 | 4.872 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0.895 |
Other Current Liabilities, Total | 0.728 | 2.415 | 4.048 | 5.695 | 4.506 |
Total Liabilities | 14.056 | 15.006 | 45.426 | 48.17 | 46.757 |
Total Long Term Debt | 0.219 | 0.235 | 0 | 0 | 0 |
Long Term Debt | 0 | 0 | 0 | 0 | |
Other Liabilities, Total | 3.456 | 3.475 | 27.48 | 27.646 | 29.794 |
Total Equity | 67.202 | 81.507 | 64.514 | 77.189 | 92.443 |
Common Stock | 0.3 | 0.3 | 0.304 | 0.303 | 0.3 |
Additional Paid-In Capital | 296.476 | 296.445 | 298.518 | 295.636 | 292.67 |
Retained Earnings (Accumulated Deficit) | -229.375 | -215.135 | -230.025 | -214.321 | -197.249 |
Treasury Stock - Common | 0 | -4.21 | -4.21 | -2.991 | |
Other Equity, Total | -0.199 | -0.103 | -0.073 | -0.219 | -0.287 |
Total Liabilities & Shareholders’ Equity | 81.258 | 96.513 | 109.94 | 125.359 | 139.2 |
Total Common Shares Outstanding | 29.9594 | 29.9591 | 29.9331 | 29.7976 | 29.6605 |
Current Port. of LT Debt/Capital Leases | 0.06 | 0.058 | |||
Capital Lease Obligations | 0.219 | 0.235 |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
Netto indkomst/Startlinje | -54.573 | -80.107 | -40.658 | -20.025 |
Likvider Fra Driftsaktiviteter | -52.643 | -22.888 | -24.589 | -8.02 |
Likvider Fra Driftsaktiviteter | 0.091 | 0.098 | 0.05 | 0.002 |
Ikke-Likvide Ting | 27.809 | 31.352 | 6.269 | 9.051 |
Cash Taxes Paid | 0 | 0 | ||
Likvid Rente Betalt | 0.007 | 0 | 0 | |
Ændringer i Driftskapital | -25.97 | 25.769 | 9.75 | 2.952 |
Likvider fra Investeringsaktiviteter | -0.382 | -0.041 | -0.242 | 0 |
Kapitaludgifter | -0.382 | -0.041 | -0.242 | 0 |
Likvider fra Financieringsaktiviteter | 107.171 | 52.409 | 4.89 | 31.741 |
Udstedelse (Pensionering) af Aktier, Netto | -0.617 | 20.813 | -0.375 | 28.596 |
Udstedelse (Pensionering) af Gæld, Netto | 0.293 | 32.118 | 5.265 | 3.145 |
Netto Ændring i Likviditet | 54.149 | 29.036 | -19.941 | 23.721 |
Financiering af Cash-Flow-Ting | 107.495 | -0.522 | ||
Udenlandsk Børs Effekter | 0.003 | -0.444 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -14.24 | -54.573 | -69.463 | -53.759 | -36.687 |
Cash From Operating Activities | -15.653 | -52.643 | -38.281 | -23.082 | -12.551 |
Cash From Operating Activities | 0.032 | 0.091 | 0.059 | 0.029 | 0.006 |
Non-Cash Items | 0.179 | 27.809 | 25.729 | 23.505 | 21.675 |
Changes in Working Capital | -1.624 | -25.97 | 5.394 | 7.143 | 2.455 |
Cash From Investing Activities | 0 | -0.382 | -0.346 | -0.285 | -0.041 |
Capital Expenditures | 0 | -0.382 | -0.346 | -0.285 | -0.041 |
Cash From Financing Activities | -0.014 | 107.171 | 106.767 | 106.068 | 108.444 |
Financing Cash Flow Items | 0 | 107.495 | -5.52 | -5.428 | -2.797 |
Issuance (Retirement) of Stock, Net | 0 | -0.617 | 112.287 | 111.496 | 111.241 |
Issuance (Retirement) of Debt, Net | -0.014 | 0.293 | 0 | 0 | 0 |
Foreign Exchange Effects | -0.087 | 0.003 | -0.011 | 0.005 | -0.003 |
Net Change in Cash | -15.754 | 54.149 | 68.129 | 82.706 | 95.849 |
Cash Interest Paid | 0.007 |
Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
---|---|---|---|---|---|---|
Satterfield (Thomas A Jr) | Individual Investor | 7.2983 | 2197825 | 623278 | 2022-12-31 | LOW |
Vifor (International), Ltd | Corporation | 6.6269 | 1995643 | 0 | 2023-03-15 | LOW |
EISA-ABC LLC | Corporation | 5.719 | 1722237 | 0 | 2023-03-15 | LOW |
Goldberg (Itzhak D) | Individual Investor | 5.6193 | 1692199 | 4213 | 2023-03-15 | LOW |
Venkatesan (Jay R) | Individual Investor | 3.9765 | 1197498 | 0 | 2023-03-15 | LOW |
BVF Partners L.P. | Hedge Fund | 3.5574 | 1071297 | 0 | 2022-12-31 | LOW |
Nantahala Capital Management, LLC | Hedge Fund | 3.4308 | 1033145 | -32867 | 2022-12-31 | MED |
Ganzi (Victor F.) | Individual Investor | 3.25 | 978698 | 0 | 2023-03-15 | LOW |
CM Management, LLC | Investment Advisor | 2.4313 | 732178 | 132178 | 2022-12-31 | MED |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.1386 | 644035 | 675 | 2022-12-31 | LOW |
Park West Asset Management LLC | Hedge Fund | 1.2311 | 370724 | 0 | 2022-12-31 | MED |
Bridgeway Capital Management, LLC | Investment Advisor | 0.5811 | 175000 | 0 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5593 | 168436 | -451 | 2022-12-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.4041 | 121700 | -87277 | 2022-12-31 | HIGH |
Omenn (Gilbert S) | Individual Investor | 0.2667 | 80326 | 0 | 2023-03-15 | LOW |
Millennium Management LLC | Hedge Fund | 0.2502 | 75342 | -50261 | 2022-12-31 | HIGH |
Raymond James & Associates, Inc. | Research Firm | 0.1992 | 60000 | 0 | 2022-12-31 | LOW |
Birchview Capital, LP | Investment Advisor | 0.1806 | 54392 | 0 | 2022-12-31 | LOW |
Ergoteles Capital | Hedge Fund | 0.1757 | 52913 | -25944 | 2022-12-31 | HIGH |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.1696 | 51069 | 1188 | 2022-12-31 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group500K+
Handlende
92K+
Månedlkige, aktive klienter
$53M+
Månedlig investeringsvolumen
$30M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Angion Biomedica Corp. Company profile
Om Angion Biomedica Corp.
Angion Biomedica Corp. er en biofarmaceutisk virksomhed i den sene fase. Virksomheden fokuserer på opdagelse, udvikling og kommercialisering af små molekylære terapier til behandling af akutte organskader og fibrotiske sygdomme. Virksomhedens førende produktkandidat er ANG-3777. Selskabets pipeline omfatter ANG-3070, rho kinase 2 (ROCK2) og CYP11B2. ANG-3777 er et hepatocytvækstfaktor (HGF)-mimetikum, som virksomheden er ved at evaluere i forbindelse med flere akutte organskader og relaterede indikationer, herunder akut nyreskade (AKI) og skader på andre organer, såsom lunger, centralnervesystemet (CNS) og hjertet. ANG-3777 evalueres også til indikationer inden for akut lungeskade (ALI) med fokus på akut respiratorisk distress syndrom (ARDS) samt akutte CNS-skader. Selskabets andre programmer er til behandling af fibrotiske sygdomme, ANG-3070, en tyrosinkinasehæmmer (TKI), og en hæmmer af rho kinase 2 (ROCK2).
Industry: | Biotechnology & Medical Research (NEC) |
7-57 Wells Avenue
NEWTON
MASSACHUSETTS 02459
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com